Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent therapeutic strategy for multiple sclerosis].

Y Itoyama1

  • 1Department of Neurology, Tohoku University School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|September 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica.

Biochemistry and biophysics reports·2017
Same author

PET study in a patient with spinocerebellar degeneration before and after long-term administration of thyrotropin releasing hormone.

Behavioural neurology·2014
Same author

Differential diagnosis of early stage Huntington's disease from dentatorubral-pallidoluysian atrophy by DNA analysis.

European journal of neurology·2013
Same author

A family with mild clinical manifestations of spinocerebellar ataxia type 1 (SCA1): correlation with smaller CAG repeats.

European journal of neurology·2013
Same author

A clinical variance in familial amyotrophic lateral sclerosis with a point mutation in Cu/Zn superoxide dismutase gene.

European journal of neurology·2013
Same author

A Japanese family with Machado-Joseph disease characterized by initial emaciation and myoclonus.

European journal of neurology·2013
Same journal

[Let's present at a regional meeting].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Editor's Note].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Notice for Members].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 250th Kyushu Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 116th Tohoku Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Metagenomic analysis for central nervous system infections: clinical utility and future directions].

Rinsho shinkeigaku = Clinical neurology·2026
See all related articles

Multiple Sclerosis (MS) is a central nervous system inflammatory disease. Treatments like interferon beta and glatiramer acetate help manage MS attacks and alter its course.

Area of Science:

  • Neurology
  • Immunology
  • Neuroinflammation

Context:

  • Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS).
  • MS prevalence is lower in Asian countries, with a higher frequency of the optic-spinal form compared to Western nations.
  • Etiology is unknown, with proposed factors including immune mechanisms, infectious agents, and genetics.

Purpose:

  • To outline the characteristics and treatment landscape of Multiple Sclerosis.
  • To highlight differences in MS presentation and prevalence between Asian and Western countries.
  • To review current therapeutic strategies for managing MS.

Summary:

  • MS involves neurological deficits characterized by relapses and remissions, and multiple CNS lesions.

Related Experiment Videos

  • While steroid therapy may reduce inflammation, it doesn't alter the disease's natural history.
  • Interferon beta and other immunomodulators like glatiramer acetate are approved for altering MS progression and reducing attacks.

    • Impact:

    • Provides an overview of MS pathophysiology and clinical characteristics.
    • Discusses epidemiological variations of MS globally.
    • Summarizes the efficacy of disease-modifying therapies in managing Multiple Sclerosis.